Abstract
The use of targeted molecular therapies (TMT) such as bevacizumab, sunitinib, and sorafenib prior to cytoreductive nephrectomy (CN) holds promise as a rational treatment paradigm for patients with metastatic renal cell carcinoma (mRCC). To analyze their safety in pre-surgical setting, we evaluated surgical parameters and perioperative complications in patients treated with TMTs prior to CN and compared them to a matched patient cohort who underwent initial CN.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
